On January 20, Shandong Wohua Pharmaceutical Co.Ltd(002107) released the annual report of 2021. In 2021, when the prices of Chinese herbal medicine raw materials, packaging materials and energy rose sharply, and the company’s marketing was blocked due to the occasional regional epidemic, Shandong Wohua Pharmaceutical Co.Ltd(002107) on the one hand, optimize the production process, improve the procurement accuracy and reduce the cost, on the other hand, pay equal attention to independent R & D and joint R & D, tap the clinical value of products, continue to deepen the marketing reform and promote intelligent manufacturing, The annual revenue was 943 million yuan, the net profit was 163 million yuan and the earnings per share was 0.28 yuan. Meanwhile, the company plans to distribute a cash dividend of 2.60 yuan for every 10 shares.
In terms of production, during the reporting period, the prices of Chinese herbal medicines with large consumption of main raw materials, especially wild Chinese herbal medicines, increased significantly. Compared with the beginning of 2021, the prices of Rehmannia glutinosa, epimedium and leech in terms of Chinese herbal medicines increased by more than 350%, 160% and 100% respectively, and the prices of salt Psoralea corylifolia, Rhizoma Drynariae and peony bark also increased significantly. In order to reduce the cost, the company expands the flexible combination of multiple measures such as direct mining in producing areas, so as to minimize the procurement cost. At the same time, we launched the production process optimization project of Gushukang capsule, completed the research of the project of “advanced manufacturing key technology and demonstration research of traditional Chinese medicine oral preparations” and entered the commissioning stage, so as to provide reference and temsector for the intelligent transformation of other product production lines of the enterprise.
In terms of R & D, Shandong Wohua Pharmaceutical Co.Ltd(002107) continues to increase R & D investment, pay equal attention to independent R & D and joint R & D, deeply tap the clinical value of products, and constantly broaden and deepen the “moat”. Shandong Wohua Pharmaceutical Co.Ltd(002107) independent research and development has obtained 4 national invention patent certificates, 12 joint research and development projects have been successfully promoted, and provincial and municipal technological innovation projects and scientific and technological plan projects have been approved. On December 3, 2021, the state released the 2021 edition of the national medical insurance drug catalogue, and wohuaxinkeshu tablets were changed from medical insurance class B to class A.
The company said that in 2022, it will maintain strategic concentration, focus on the main business of R & D, production and sales of Chinese patent medicine, and fully explore the potential of exclusive products; Accelerate the construction of a multi variety and coordinated marketing platform “expressway” with “four exclusive medical insurance pillar products” as the core; Continue to promote lean production and intelligent upgrading, and achieve the goal of stable and sustainable growth of sales revenue and profit.
